Send to a Friend Share

Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Catalysts on the Horizon

February 9, 2012 11:14 AM EST
OSUR Hot Sheet
Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 16 | New: 82
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "While still mostly a catalyst story, quarterly results were in line to slightly ahead of expectations. The Q1/12 revenue outlook of $21M appears soft due to substance abuse testing, but our bullish thesis remains intact...HCV waived sites yet to come...OSUR reported $800k of HCV sales, ahead of our $500k estimate, mostly to non-waived public health centers. OSUR continues to train its selling partners on OraQuick HCV, including physician distributors, Merck (NYSE: MRK) sales reps as well as Merck inside sales reps...We reduce 2012E sales to $100M."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $11.00 yesterday, with a 52 week range of $6.18-$11.78.


Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Genuity Capital Markets

Add Your Comment





Follow StreetInsider.com On Twitter